Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRINASDAQ:BPTHNASDAQ:CMMBNASDAQ:FWPAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.61-0.4%$0.75$0.58▼$2.22$5.77M0.37919,230 shs22,345 shsBPTHBio-Path$0.18$0.16$0.12▼$4.55$1.50M-0.141.25 million shs30,718 shsCMMBChemomab Therapeutics$1.37$1.21$0.78▼$2.55$19.67M0.55211,053 shs10,830 shsFWPAYForward Pharma A/S$300.00$424.38$1.43▼$5.33$6M-42.677 shs11 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-3.96%-5.01%-24.23%-37.10%-41.55%BPTHBio-Path-5.26%+5.88%+28.57%-2.70%-90.58%CMMBChemomab Therapeutics-2.14%-0.72%+2.24%-15.43%+50.75%FWPAYForward Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.1172 of 5 stars3.53.00.00.01.40.01.3BPTHBio-Path1.9352 of 5 stars3.50.00.00.02.00.01.3CMMBChemomab Therapeutics3.7714 of 5 stars3.55.00.00.04.11.71.3FWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$2.75350.08% UpsideBPTHBio-Path 3.00Buy$20.0011,011.11% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50520.44% UpsideFWPAYForward Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BPTH, BFRI, FWPAY, and CMMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.755/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$38.00M0.15N/AN/A$3.16 per share0.19BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/ACMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/AFWPAYForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest BPTH, BFRI, FWPAY, and CMMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.530.94BPTHBio-PathN/A0.860.86CMMBChemomab TherapeuticsN/A4.574.57FWPAYForward Pharma A/SN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BPTHBio-Path5.74%CMMBChemomab Therapeutics46.05%FWPAYForward Pharma A/S2.63%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera1.20%BPTHBio-Path0.72%CMMBChemomab Therapeutics11.91%FWPAYForward Pharma A/S71.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera709.45 million7.73 millionNo DataBPTHBio-Path108.31 million5.73 millionOptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableFWPAYForward Pharma A/SN/A20,0007,000Not OptionableBPTH, BFRI, FWPAY, and CMMB HeadlinesRecent News About These CompaniesThe U.S. Shakes Up Global Pharma Supply ChainsNovember 14, 2024 | seekingalpha.comBayer's rising prostate cancer star Nubeqa crosses blockbuster barrier as Xarelto continues downward descentNovember 13, 2024 | fiercepharma.comA setback for the tau approach to Alzheimer’sNovember 3, 2024 | statnews.comPromising Prospects for Larimar Therapeutics: Buy Rating on Innovative Friedreich’s Ataxia TherapyOctober 31, 2024 | markets.businessinsider.comAstellas Pharma Faces Currency Losses in FY2024October 31, 2024 | markets.businessinsider.comLeo Pharma unveils up to 250 layoffs and relocations amid CEO's revampOctober 11, 2024 | fiercepharma.comEmployers Haven’t a Clue How Their Drug Benefits Are ManagedOctober 10, 2024 | msn.comCustomer Refusing To Pay Forward $42 Order Backed: 'Streak Ends With Me'October 9, 2024 | msn.comOur StoryOctober 8, 2024 | forward.comWIN Launches its Pay It Forward CampaignSeptember 30, 2024 | fenderbender.comHow a farm is restoring the connection between veterans and their familiesSeptember 30, 2024 | fox17online.comAppeals Court resurrects PhRMA's lawsuit challenging pricing provisions in IRASeptember 25, 2024 | fiercepharma.comPontera Links With New ‘Tech-Forward’ Recordkeeper in Wake of Fidelity ReversalSeptember 20, 2024 | thinkadvisor.comHigh insulin prices spur a federal lawsuit against three pharmacy benefit managersSeptember 20, 2024 | wqad.comHow Does Forward Air Corp (FWRD) Stack Up Against Its Industry Peers?September 20, 2024 | bovnews.comBiogen protects Tecfidera via $1.25bn deal with ForwardSeptember 4, 2024 | pharmaphorum.comForward Air gains after report activist Ancora pushing for saleAugust 22, 2024 | msn.comForward-Thinking HVAC Solutions for Tomorrow’s HomesApril 26, 2024 | msn.comThe Analyst Landscape: 4 Takes On Forward AirApril 3, 2024 | markets.businessinsider.comPaying it forward: Check in with anotherMarch 31, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, BFRI, FWPAY, and CMMB Company DescriptionsBiofrontera NASDAQ:BFRI$0.61 0.00 (-0.44%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Bio-Path NASDAQ:BPTH$0.18 0.00 (0.00%) As of 10:56 AM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Chemomab Therapeutics NASDAQ:CMMB$1.37 0.00 (0.00%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Forward Pharma A/S NASDAQ:FWPAYForward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
